Across TCGA pan-cancer cohorts, ERVMER61-1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ERVMER61-1 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ERVMER61-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ERVMER61-1 expression acts as an unfavorable survival marker.
UCEC and ESCA are the cancer types where ERVMER61-1 Mutation most reproducibly stratifies survival.